Shanghai Henlius Biotech 2025 Annual Report: Key Investor Insights and Price-Sensitive Highlights

1. Strong Financial Performance and Profitability

• Revenue Growth: The Group reported a revenue of RMB 6.67 billion for 2025, up 16% from RMB 5.72 billion in 2024.
• Profit Surge: Net profit attributable to owners of the parent reached RMB 827 million in 2025, up slightly from RMB 820 million in 2024, maintaining profitability after achieving a turnaround from losses in 2022 and prior years.
• Gross Profit: Gross profit for 2025 amounted to RMB 4.98 billion, reflecting the Group’s improved cost management and operational efficiency.
• EPS: Basic earnings per share for 2025 was RMB 1.52, up from RMB 1.51 in 2024.
• Balance Sheet Strength: Total assets increased to RMB 12.36 billion (2024: RMB 10.60 billion), while net assets grew to RMB 3.96 billion (2024: RMB 3.01 billion).
• Improved Gearing: The Group’s gearing ratio remained stable, with interest-bearing bank and other borrowings at RMB 3.60 billion and cash and cash equivalents at RMB 579 million.

2. No Final Dividend for 2025

• No Dividend Declared: The Board does not recommend a final dividend for the year 2025. The company also reported that as of year-end, there were no distributable reserves, which may disappoint income-focused investors and could be a short-term share price headwind.
• Profit Distribution Policy: The Group maintains a flexible profit distribution policy, prioritizing cash dividends when feasible, but reserves the right to distribute profits in shares or a combination in line with operational performance and capital needs.

3. Capital Structure and Share Movements

• No Share Buybacks: The company and its subsidiaries did not purchase, sell, or redeem any of the Company’s listed securities (including treasury shares) during 2025.
• H Shares Full Circulation: A significant event was the completion of the conversion of 182,645,856 Unlisted Shares into H Shares on February 4, 2026, with trading commencing on February 5, 2026. This move increases the market liquidity of H Shares and could affect supply-demand dynamics and share price volatility in the secondary market.

4. Major Customers and Supplier Dependence

• Customer Concentration Risk: The Group’s five largest customers accounted for 56.9% of total revenue, with the single largest customer representing 37% of revenue in 2025. This high concentration exposes the company to significant counterparty risk, which investors should monitor closely.
• Supplier Diversification: Purchases from the five largest suppliers were less than 30% of total purchases, indicating low supplier concentration risk.

5. Corporate Governance, Board and Shareholder Matters

• Board and Management Changes: There were notable changes to the company secretary and authorized representatives in March 2026. All directors and supervisors have three-year service contracts subject to retirement and rotation.
• Share Option and RSU Schemes: In July 2025, the Company adopted new H Share Option and RSU schemes. These schemes are performance-based, with vesting tied to both financial and R&D KPIs, as well as market capitalization targets. Potential dilution from these schemes may impact future earnings per share.
• Remuneration: Total remuneration for directors, supervisors, and the chief executive in 2025 was RMB 36.96 million, including share-based payments. Four non-director, non-supervisor, non-CEO employees received remuneration exceeding RMB 11.5 million each, reflecting competitive pay for key talent.

6. Related Party and Connected Transactions

• Continuing Connected Transactions: The Group renewed property leasing agreements with related parties Clone High Tech and Fukun Pharmaceutical until 2028. All connected transactions were reviewed and confirmed as fair, reasonable, and in the interests of shareholders.
• Revenue from Related License Agreement: The Group recognized RMB 128.8 million in revenue from R&D services under a License Agreement with Fosun Pharma Industrial Development.

7. Privatisation Attempt and Termination

• Privatisation Proposal Terminated: The Company was subject to a proposed privatisation by Fosun New Medicine by way of merger by absorption and delisting from the Hong Kong Stock Exchange. However, the proposal was not approved by H Shareholders at the class meeting on January 22, 2025, and the plan was terminated. This could be price sensitive as it preserves the company’s public listing and may affect investor expectations regarding control and future offers.

8. Legal Proceedings and Compliance

• Ongoing Legal Dispute: The Group has an ongoing legal dispute involving an investment management agreement with oOo Securities (HK) Group Limited (formerly AMTD Global Markets Limited). Court proceedings have been stayed in favor of arbitration. The company has completed internal control rectifications related to the incident, and the HK Stock Exchange issued a disciplinary action in September 2025. This does not materially affect daily operations but highlights governance risks investors should note.
• Compliance: The Group reported full compliance with all relevant laws and regulations during 2025, and continues to strengthen its internal controls and risk management mechanisms.

9. Outlook and Strategic Direction

• Global Expansion: The Group continues to focus on internationalization, expanding its overseas revenue, and building a scalable, sustainable growth model (“Globalization 2.0”).
• R&D Investment: The company capitalized RMB 976 million of development expenditure in 2025, underscoring its commitment to pipeline innovation. R&D expenses totaled RMB 1.52 billion in 2025.
• No Material Subsequent Events: Aside from the H Share circulation and regular board changes, no other material events have occurred since year-end that would impact the company’s financial standing.

10. Other Noteworthy Items

• Donations: The Group made substantial charitable donations of RMB 91.8 million during the period.
• Audit and Controls: Ernst & Young served as the auditor, receiving RMB 3.01 million for audit services and RMB 2.46 million for non-audit services in 2025. The Group’s internal controls were reviewed and found to be effective and adequate.
• Risk Factors: Investors should monitor high customer concentration, ongoing legal disputes, and the impact of new equity incentive schemes on dilution and management alignment.

Disclaimer

This article is a summary and analysis of Shanghai Henlius Biotech, Inc.’s 2025 Annual Report, prepared for informational purposes only. It does not constitute investment advice or a recommendation to buy or sell any securities. Investors should conduct their own due diligence and consult professional advisors before making investment decisions. The company’s performance and share price may be affected by the events, risks, and developments highlighted above.

View HENLIUS Historical chart here